Stockreport

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

ImmunityBio, Inc.  (IBRX) 
PDF Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations85% enrolled with anticipated completion in Q2 2026 with [Read more]